P-46

Jumi Popoola
American Association for Cancer Research
James F. Amatruda
Children’s Hospital Los Angeles

Alexander Baras
Johns Hopkins School of Medicine

Philippe Bedard
University of Toronto

Brady Bernard
Providence Cancer Institute

Marcia Cruz-Correa
University of Puerto Rico Medical Sciences

Christina Curtis
Stanford University

Rodrigo Dienstmann
Vall d’Hebron Institute of Oncology

Margaret Foti
American Association for Cancer Research

Kevin Haigis
Dana-Farber Cancer Institute

Brian Henick
Columbia University

Maud Kamal
Gustave Roussy Cancer Campus

Kenneth L. Kehl
Dana-Farber Cancer Institute

Marilyn Li
Children’s Hospital of Philadelphia

Shannon Jones McCall
Duke University

Gerrit Meijer
Netherlands Cancer Institute

Christine Micheel
Vanderbilt University Medical Center

Lucio Miele
The Louisiana State University Health Sciences Center

Kyong Hwa Park
Korea University Anum Hospital

Gregory J. Riely
Memorial Sloan Kettering Cancer Center

Nikolaus Schultz
Memorial Sloan Kettering Cancer Center

Stephan Schürer
University of Miami Miller School of Medicine

Kelli Rasmussen
American Association for Cancer Research

Shawn M. Sweeney
American Association for Cancer Research

Alejandro Sweet-Cordero
University of California San Francisco

Adam Taylor
Sage Bionetworks

Zenta Walther
Yale School of Medicine

Peng Wang
University of Chicago

on behalf of the AACR Project GENIE® Consortium
American Association for Cancer Research

AACR Project GENIE® is an international, open-access, pan-cancer registry of real-world clinico-genomic data built through data sharing across 20 leading academic cancer centers, for improving clinical decision making. The registry catalyzes correlation of genotypic patterns with clinical features by aggregating clinical-grade sequencing data from tumors of patients treated at participating centers and linking these genetic profiles with data from each patient’s experience with cancer. The registry hosts ~300,000 sequenced samples from ~250,000 patients, including tumor and cell-free DNA (cfDNA) sequencing data representing multiple cancer types across diverse clinical and demographic populations. This creates a unique resource for addressing questions that no single institution could answer alone.

The scientific utility of GENIE data spans several domains directly relevant to the GA4GH Cancer Community. The longitudinal nature of GENIE data enables analyses of genomic evolution, clonal dynamics and resistance mechanisms across the cancer treatment period. For variant interpretation, the scale of GENIE has proven transformative: analyses of the data reveal differential prevalence, co-mutation patterns, and demographic correlates across more than 100 cancer types. The registry also enables discovery of putative novel driver alterations in rare tumors.

Additionally, GENIE uses sponsored research to fund detailed clinical annotation on relevant subsets of the registry, generating regulatory-grade datasets capable of supporting regulatory use cases. This illustrates how community-built, standards-harmonized data resources can shape clinical policy. The addition of cfDNA sequencing alongside tumor sequencing further extends GENIE's utility for longitudinal disease monitoring and biomarker discovery. The GENIE BioPharma Collaborative (BPC) subset cohorts, comprising ~20,000 patients with deep clinical curation, also provide deeper insights into the patient journey.

The GA4GH Strategic Road Map prioritizes responsible, scalable frameworks for global genomic and clinical data sharing that translate into tangible clinical and research utility. AACR Project GENIE demonstrates what is achievable when those principles are operationalized at scale in oncology. GENIE offers a proven model and an active partner for demonstrating how open-access clinico-genomic infrastructure can accelerate precision oncology globally.